Search Results - "Boschini, Cristina"

Validation of the acute leukemia‐EBMT score for prediction of mortality following allogeneic stem cell transplantation in a multi‐center GITMO cohort by Shouval, Roni, Bonifazi, Francesca, Fein, Joshua, Boschini, Cristina, Oldani, Elena, Labopin, Myriam, Raimondi, Roberto, Sacchi, Nicoletta, Dabash, Osamah, Unger, Ron, Mohty, Mohamad, Rambaldi, Alessandro, Nagler, Arnon

“…Predictive models may help in determining the risk/benefit ratio of allogeneic hematopoietic stem cell transplantation (HSCT) in acute leukemia (AL). Using a…”
Get full text

Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival by Salmoiraghi, Silvia, Montalvo, Marie Lorena Guinea, Ubiali, Greta, Tosi, Manuela, Peruta, Barbara, Zanghi, Pamela, Oldani, Elena, Boschini, Cristina, Kohlmann, Alexander, Bungaro, Silvia, Intermesoli, Tamara, Terruzzi, Elisabetta, Angelucci, Emanuele, Cavattoni, Irene, Ciceri, Fabio, Bassan, Renato, Rambaldi, Alessandro, Spinelli, Orietta

Get full text

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival by Tarella, Corrado, Gueli, Angela, Delaini, Federica, Rossi, Andrea, Barbui, Anna Maria, Gritti, Giuseppe, Boschini, Cristina, Caracciolo, Daniele, Bruna, Riccardo, Ruella, Marco, Gottardi, Daniela, Passera, Roberto, Rambaldi, Alessandro

“…Primary refractory disease is a main challenge in the management of non-Hodgkin's Lymphoma (NHL). This survey was performed to define the rate of refractory…”
Get full text

Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas by Gritti, Giuseppe, Boschini, Cristina, Rossi, Andrea, Delaini, Federica, Grassi, Anna, Algarotti, Alessandra, Micò, Caterina, Trezzi, Rosangela, Gianatti, Andrea, Barbui, Anna Maria, Rambaldi, Alessandro

“…Outcome of systemic peripheral T-cell lymphomas (PTCL) is unsatisfactory and no controlled clinical study guides the therapy. Phase II studies suggest to…”
Get full text

Safety Profile of Semaglutide in People Aged 55 Years and Over: Pooled Data from the PIONEER, SUSTAIN, and STEP Phase 3 Clinical Programmes (P11-9.014) by Sabbagh, Marwan, Boschini, Cristina, Cohen, Sharon, Fugger, Magnus, Jessen, Frank, Martino, Gabriel Gerardo, Pedersen, Sue, Tarazona, Luis Rafael Solís, Aroda, Vanita

“…Abstract only…”
Get full text

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes by Dahl, Kirsten, Brooks, Ashley, Almazedi, Firas, Hoff, Søren Tetens, Boschini, Cristina, Bækdal, Tine A.

“…Aim To assess the effects of oral semaglutide on postprandial glucose and lipid metabolism, and gastric emptying, in subjects with type 2 diabetes (T2D)…”
Get full text

Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects by van Hout, Marloes, Forte, Pablo, Jensen, Thomas B., Boschini, Cristina, Bækdal, Tine A.

“…Background Prescribing information instructs taking oral semaglutide (a glucagon-like peptide-1 analogue) in the fasting state, followed by a post-dose fasting…”
Get full text

Allo-HCT regimens with low toxicity needed in older patients with acute myeloid leukaemia – Authors' reply by Rambaldi, Alessandro, Masciulli, Arianna, Boschini, Cristina

“…[...]the intent of our study was to show that a reduced toxicity, albeit myeloablative, programme (busulfan plus fludarabine) could substantially reduce the…”
Get full text

Correction to: Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects by van Hout, Marloes, Forte, Pablo, Jensen, Thomas B., Boschini, Cristina, Bækdal, Tine A.

Get full text

Characteristics of graft‐versus‐host disease occurring after alemtuzumab‐containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival by Finazzi, Maria C., Boschini, Cristina, Craddock, Charles, Rambaldi, Alessandro, Ward, Janice, Malladi, Ram K.

“…Summary T‐cell depletion with alemtuzumab represents an effective form of graft‐versus‐host disease (GVHD) prophylaxis after allogeneic haematopoietic stem…”
Get full text

Safety profile of semaglutide in people aged 55 years and over: pooled data from the PIONEER, SUSTAIN and STEP phase 3 clinical programmes by Sabbagh, Marwan, Boschini, Cristina, Cohen, Sharon, Fugger, Magnus, Jessen, Frank, Martino, Gabriel Gerardo, Pedersen, Sue D., Tarazona, Luis Rafael Solís, Aroda, Vanita R.

“…Background The risk of Alzheimer’s disease (AD) increases with age. The glucagon‐like peptide‐1 analogue semaglutide, approved for type 2 diabetes (T2D) and…”
Get full text

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial by Rambaldi, Alessandro, Dr, Grassi, Anna, MD, Masciulli, Arianna, MSc, Boschini, Cristina, MSc, Micò, Maria Caterina, MD, Busca, Alessandro, MD, Bruno, Benedetto, MD, Cavattoni, Irene, MD, Santarone, Stella, MD, Raimondi, Roberto, MD, Montanari, Mauro, MD, Milone, Giuseppe, MD, Chiusolo, Patrizia, MD, Pastore, Domenico, MD, Guidi, Stefano, MD, Patriarca, Francesca, MD, Risitano, Antonio M, MD, Saporiti, Giorgia, MD, Pini, Massimo, MD, Terruzzi, Elisabetta, MD, Arcese, William, Prof, Marotta, Giuseppe, MD, Carella, Angelo Michele, MD, Nagler, Arnon, Prof, Russo, Domenico, Prof, Corradini, Paolo, Prof, Alessandrino, Emilio Paolo, MD, Torelli, Giovanni Fernando, MD, Scimè, Rosanna, MD, Mordini, Nicola, MD, Oldani, Elena, BiolSc, Marfisi, Rosa Maria, MSc, Bacigalupo, Andrea, MD, Bosi, Alberto, Prof

“…Summary Background The standard busulfan–cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients…”
Get full text

Excess risk estimation for matched cohort survival data by Boschini, Cristina, Andersen, Klaus K, Scheike, Thomas H

“…We present an excess risk regression model for matched cohort data, where the occurrence of some events for individuals with a disease is compared to that of…”
Get full text

Excess cumulative incidence estimation for matched cohort survival studies by Boschini, Cristina, Andersen, Klaus K., Jacqmin‐Gadda, Hélène, Joly, Pierre, Scheike, Thomas H.

“…We suggest a regression approach to estimate the excess cumulative incidence function (CIF) when matched data are available. In a competing risk setting, we…”
Get full text

Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas by Cortelazzo, Sergio, Tarella, Corrado, Gianni, Alessandro Massimo, Ladetto, Marco, Barbui, Anna Maria, Rossi, Andrea, Gritti, Giuseppe, Corradini, Paolo, Di Nicola, Massimo, Patti, Caterina, Mulé, Antonino, Zanni, Manuela, Zoli, Valerio, Billio, Atto, Piccin, Andrea, Negri, Giovanni, Castellino, Claudia, Di Raimondo, Francesco, Ferreri, Andrés J M, Benedetti, Fabio, La Nasa, Giorgio, Gini, Guido, Trentin, Livio, Frezzato, Maurizio, Flenghi, Leonardo, Falorio, Simona, Chilosi, Marco, Bruna, Riccardo, Tabanelli, Valentina, Pileri, Stefano, Masciulli, Arianna, Delaini, Federica, Boschini, Cristina, Rambaldi, Alessandro

“…Purpose The benefit of high-dose chemotherapy with autologous stem-cell transplantation (ASCT) as first-line treatment in patients with diffuse large B-cell…”
Get full text

Pregnancy outcomes in women with neurofibromatosis 1: a Danish population-based cohort study by Kenborg, Line, Boschini, Cristina, Bidstrup, Pernille E, Dalton, Susanne O, Doser, Karoline, Nielsen, Thomas T, Krøyer, Anja, Johansen, Christoffer, Frederiksen, Kirsten, Sørensen, Sven Asger, Hove, Hanne, Østergaard, John R, Mulvihill, John J, Winther, Jeanette F

“…The probability of a pregnancy, live birth, stillbirth and abortion has never been assessed in women with neurofibromatosis 1 (NF1) in a large population-based…”
Get more information

The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy by Rambaldi, Alessandro, Boschini, Cristina, Gritti, Giuseppe, Delaini, Federica, Oldani, Elena, Rossi, Andrea, Barbui, Anna Maria, Caracciolo, Daniele, Ladetto, Marco, Gueli, Angela, Crescenzo, Alberto, Passera, Roberto, Devizzi, Liliana, Patti, Caterina, Gianni, Alessandro Massimo, Tarella, Corrado

“…The peripheral blood lymphocyte to monocyte ratio (LMR) at diagnosis can be clinically relevant in patients with diffuse large B‐cell lymphoma (DLBCL). We…”
Get full text

Impact of Comorbidity Burden in Treatment and Outcome of Older Patients with Indolent Non-Hodgkin Lymphomas by Gritti, Giuseppe, Stefanoni, Paola, Boschini, Cristina, Rossi, Andrea, Barbui, Anna Maria, Rambaldi, Alessandro

“…Introduction: Despite the growing interest about the optimal treatment of older patients with cancer, only few data are available for indolent non-Hodgkin…”
Get full text

Tenascin-C Is Highly Expressed in T-Cell Non-Hodgkin Lymphomas and Represents an Attractive Target for Radioimmunotherapy by Gritti, Giuseppe, Gianatti, Andrea, Petronzelli, Fiorella, Boschini, Cristina, Rossi, Riccardo, Trezzi, Rosangela, Rossi, Andrea, Barbui, Anna Maria, Rambaldi, Alessandro

“…Introduction: Tenascins are a family of large glycoproteins present in extracellular matrix, overexpressed in tumors compared to healthy tissues. Tenatumomab…”
Get full text

Risk of late health effects after soft-tissue sarcomas in childhood - a population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia research programme by Norsker, Filippa Nyboe, Boschini, Cristina, Rechnitzer, Catherine, Holmqvist, Anna Sällfors, Tryggvadottir, Laufey, Madanat-Harjuoja, Laura-Maria, Schrøder, Henrik, Scheike, Thomas H, Hasle, Henrik, Winther, Jeanette Falck, Andersen, Klaus Kaae

“…In the 1960s only 1/3 of children with soft-tissue sarcomas survived, however with improved treatments survival today has reached 70%. Given the previous poor…”
Get more information